NTX 001
Alternative Names: NTX-001Latest Information Update: 13 Sep 2024
At a glance
- Originator Neuraptive Therapeutics
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Facial paralysis; Peripheral nerve injuries
- Preclinical Epilepsy
Most Recent Events
- 12 Sep 2024 NTX 001 receives Breakthrough Therapy status for Peripheral nerve injuries in USA
- 11 Sep 2024 Neuraptive Therapeutics plans a phase-III trial for peripheral nerve injury in January 2025 (Topical), (NCT06616025),
- 22 Feb 2024 Efficacy and adverse events data from phase IIa NEUROFUSE clinical trials in Peripheral nerve injuries released by Neuraptive Therapeutics